Invention Grant
US08278430B2 Recombinant platelet collagen receptor glycoprotein VI and its pharmaceutical use
有权
重组血小板胶原受体糖蛋白VI及其药物用途
- Patent Title: Recombinant platelet collagen receptor glycoprotein VI and its pharmaceutical use
- Patent Title (中): 重组血小板胶原受体糖蛋白VI及其药物用途
-
Application No.: US13046210Application Date: 2011-03-11
-
Publication No.: US08278430B2Publication Date: 2012-10-02
- Inventor: Kenneth J. Clemeston
- Applicant: Kenneth J. Clemeston
- Applicant Address: DE Franfurt Am Main
- Assignee: Aventis Pharma Deutschland, GmbH
- Current Assignee: Aventis Pharma Deutschland, GmbH
- Current Assignee Address: DE Franfurt Am Main
- Agency: Millen, White, Zelano, Branigan, P.C.
- Priority: EP99109094 19990507
- Main IPC: C07H21/02
- IPC: C07H21/02
Abstract:
The invention relates to Glycoprotein VI (GPVI), its isolation, purification, and methods for recombinant production. Especially, the invention relates to the use of GPVI, preferably recombinant GPVI, in the treatment of disorders and pathological events correlated directly or indirectly to blood coagulation disorders such as thrombotic and cardiovascular diseases. The extracellular recombinant protein can also be used for establishing screening assays to find potential inhibitors of the membrane bound GPVI in order to inhibit binding of thrombocytes and platelets, respectively, to collagen. Changes in GPVI can be used to monitor platelet age and exposure to thrombotic and cardiovascular diseases.
Public/Granted literature
- US20110237655A1 RECOMBINANT PLATELET COLLAGEN RECEPTOR GLYCOPROTEIN VI AND ITS PHARMACEUTICAL USE Public/Granted day:2011-09-29
Information query
